DekaBank Deutsche Girozentrale increased its holdings in Celgene Co. (NASDAQ:CELG) by 1.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 561,404 shares of the biopharmaceutical company’s stock after buying an additional 5,700 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Celgene were worth $73,985,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of CELG. Arcadia Investment Management Corp MI boosted its stake in Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 400 shares during the period. Thompson Davis & CO. Inc. boosted its stake in Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 43 shares during the period. Guidant Wealth Advisors acquired a new position in Celgene during the 3rd quarter valued at about $119,000. Motco boosted its stake in Celgene by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 159 shares during the period. Finally, Balentine LLC boosted its stake in Celgene by 83.5% during the 2nd quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 481 shares during the period. 79.74% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have issued reports on the stock. Guggenheim reissued a “buy” rating and set a $147.00 target price on shares of Celgene in a research note on Wednesday. UBS Group downgraded shares of Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 price target on the stock. in a research report on Thursday, October 26th. BMO Capital Markets dropped their price target on shares of Celgene from $163.00 to $148.00 and set an “outperform” rating on the stock in a research report on Friday, October 27th. Jefferies Group restated a “buy” rating and set a $160.00 price target on shares of Celgene in a research report on Friday, September 15th. Finally, Robert W. Baird downgraded shares of Celgene from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $162.00 to $136.00 in a research report on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and nineteen have assigned a buy rating to the company. Celgene presently has a consensus rating of “Buy” and an average target price of $131.18.

Celgene Co. (CELG) opened at $106.00 on Friday. The firm has a market cap of $83,460.00, a P/E ratio of 25.00, a PEG ratio of 0.68 and a beta of 1.77. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. Celgene Co. has a 1 year low of $94.55 and a 1 year high of $147.17.

Celgene (NASDAQ:CELG) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a net margin of 30.06% and a return on equity of 43.32%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the firm posted $1.58 earnings per share. research analysts predict that Celgene Co. will post 6.68 EPS for the current year.

TRADEMARK VIOLATION WARNING: “DekaBank Deutsche Girozentrale Boosts Stake in Celgene Co. (CELG)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/01/13/dekabank-deutsche-girozentrale-boosts-stake-in-celgene-co-celg.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related stocks with our FREE daily email newsletter.